Cardiac cell therapy: Pre-conditioning effects in cell-delivery strategies

Cytotherapy

Volumn 14, Issue 3, 2012, Pages 260-266

  Wu, Kai Hong ^a   Mo, Xu Ming ^a   Han, Zhong Chao ^b   Zhou, Bin ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Cardiac pre conditioning; Cell pre conditioning; Cell therapy; Ischemic heart disease; Stem cells

Indexed keywords

ADULT STEM CELL; APOPTOSIS; CELL DEATH; CELL SURVIVAL; CELL TYPE; EMBRYONIC STEM CELL; ENGRAFTMENT; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; ISCHEMIC HEART DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 84856944577     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.643780     Document Type: Review

References (64)

1. Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol. 2010;7:204-15.
2. Akar AR, Durdu S, Arat M, Kilickap M, Kucuk NO, Arslan O, et al. Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopa-thy. Eur J Cardiothorac Surg. 2009;36:633-43.
3. Zhang H, Chen H, Wang W, Wei Y, Hu S. Cell survival and redistribution after transplantation into damaged myocardium. J Cell Mol Med. 2010;14:1078-82.
4. Wu KH, Mo XM, Han ZC, Zhou B. Stem cell engraftment and survival in the ischemic heart. Ann Thorac Surg. 2011;92:1917-25.
5. Traverse JH, McKenna DH, Harvey K, Jorgenso BC, Olson RE, Bostrom N, et al. Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mono-nuclear stem cell administration in patients following ST-ele-vation myocardial infarction. Am Heart J. 2010;160:428-34.
6. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010;12:721-9.
7. Quyyumi AA, Waller EK, Murrow J, Esteves F, Galt J, Oshin-ski J, et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J. 2011;161:98-105.
8. Hu S, Liu S, Zheng Z, Yuan X, Li L, Lu M, et al. Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure a single-center, randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2011;57:2409-15.
9. Wu KH, Zhou B, Yu CT, Cui B, Lu SH, Han ZC, et al. Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann Thorac Surg. 2007;83:1491-8. (Pubitemid 46454258)
10. Chen K, Bai H, Arzigian M, Gao YX, Bao J, Wu WS, et al. Endothelial cells regulate cardiomyocyte development from embryonic stem cells. J Cell Biochem. 2010;111:29-39.
11. Li Z, Wilson KD, Smith B, Kraft DL, Jia F, Huang M, et al. Functional and transcriptional characterization of human embryonic stem cell-derived endothelial cells for treatment of myocardial infarction. PLoS One. 2009;4:e8443.
12. Theus MH, Wei L, Cui L, Francis K, Hu X, Keogh C, et al. In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain. Exp Neurol. 2008;210:656-70.
13. Kofidis T, de Bruin JL, Yamane T, Balsam LB, Lebl DR, Swi-jnenburg RJ, et al. Insulin-like growth factor promotes engraftment, differentiation, and functional improvement after transfer of embryonic stem cells for myocardial restoration. Stem Cells. 2004;22:1239-45. (Pubitemid 39636401)
14. Hug K, Hermeren G. Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects. Stem Cell Rev. 2011;7:761-74.
15. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res. 2008;77:134-42. (Pubitemid 351195153)
16. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008;135:799-808. (Pubitemid 351417929)
17. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res. 2009;104:1209-16.
18. Chang JC, Hsu SH, Chen DC. The promotion of chondro-genesis in adipose-derived adult stem cells by an RGD-chi-meric protein in 3D alginate culture. Biomaterials. 2009;30: 6265-75.
19. Suzuki K, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation. 2000;102:III216-21.
20. Niagara MI, Haider H, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res. 2007;100:545-55. (Pubitemid 46673264)
21. Wu KH, Mo XM, Zhou B, Lu SH, Yang SG, Liu YL, et al. Cardiac potential of stem cells from whole human umbilical cord tissue. J Cell Biochem. 2009;107:926-32.
22. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141-6.
23. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448:313-7. (Pubitemid 47080336)
24. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010; 465:808-12.
25. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation. 2009;120:408-16.
26. Tokunaga M, Liu ML, Nagai T, Iwanaga K, Matsuura K, Takahashi T, et al. Implantation of cardiac progenitor cells using self-assembling peptide improves cardiac function after myocardial infarction. J Mol Cell Cardiol. 2010;49:972-83.
27. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30-41.
28. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schul-man SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-86.
29. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108:863-8. (Pubitemid 37022130)
30. Menasche P, Hagege AA, Scorsin M, Pouzet B, Desnos M, Duboc D, et al. Myoblast transplantation for heart failure. Lancet. 2001;357:279-80. (Pubitemid 32120862)
31. Viswanathan C, Davidson Y, Cooper K, Tipnis S, Pujari G, Kurian VM. Transplantation of autologous bone marrow derived mesenchymal stem cells trans-epicardially in patients undergoing coronary bypass surgery. Indian Heart J. 2010;62:43-8.
32. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913-8. (Pubitemid 35176294)
33. Yousef M, Schannwell CM, Kostering M, Zeus T, Brehm M, Strauer BE. The BALANCE study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol. 2009;53:2262-9.
34. Grajek S, Popiel M, Gil L, Breborowicz P, Lesiak M, Czepczyn-ski R, et al. Influence of bone marrow stem cells on left ventricle perfusion and ejection fraction in patients with acute myocardial infarction of anterior wall: randomized clinical trial: impact of bone marrow stem cell intracoronary infusion on improvement of microcirculation. Eur Heart J. 2010;31:691-702.
35. Thompson CA, Nasseri BA, Makower J, Houser S, McGarry M, Lamson T, et al. Percutaneous transvenous cellular car-diomyoplasty. A novel nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol. 2003;41:1964-71. (Pubitemid 36677117)
36. Fuchs S, Kornowski R, Weisz G, Satler LF, Smits PC, Okubagzi P, et al. Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol. 2006;97:823-9.
37. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294-302. (Pubitemid 36578498)
38. Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J. 2007;28:2998-3005. (Pubitemid 350262782)
39. van Ramshorst J, Bax JJ, Beeres SL, Dibbets-Schneider P, Roes SD, Stokkel MP, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA. 2009;301:1997-2004.
40. Krause K, Jaquet K, Schneider C, Haupt S, Lioznov MV, Otte KM, et al. Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study. Heart. 2009;95:1145-52.
41. Suzuki K, Murtuza B, Fukushima S, Smolenski RT, Varela-Carver A, Coppen SR, et al. Targeted cell delivery into infarcted rat hearts by retrograde intracoronary infusion: distribution, dynamics, and influence on cardiac function. Circulation. 2004;110:II225-30. (Pubitemid 39263727)
42. Vicario J, Piva J, Pierini A, Ortega HH, Canal A, Gerardo L, et al. Transcoronary sinus delivery of autologous bone marrow and angiogenesis in pig models with myocardial injury. Cardiovasc Radiat Med. 2002;3:91-4. (Pubitemid 36434170)
43. Fukushima S, Coppen SR, Lee J, Yamahara K, Felkin LE, Terracciano CM, et al. Choice of cell-delivery route for skeletal myoblast transplantation for treating post-infarction chronic heart failure in rat. PLoS One. 2008;3:e3071.
44. Vicario J, Campo C, Piva J, Faccio F, Gerardo L, Becker C, et al. One-year follow-up of transcoronary sinus administration of autologous bone marrow in patients with chronic refractory angina. Cardiovasc Revasc Med. 2005;6:99-107. (Pubitemid 41579078)
45. Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005;111: 2198-202. (Pubitemid 40632435)
46. Blocklet D, Toungouz M, Berkenboom G, Lambermont M, Unger P, Preumont N, et al. Myocardial homing of nonmo-bilized peripheral-blood CD34 + cells after intracoronary injection. Stem Cells. 2006;24:333-6. (Pubitemid 44464802)
47. Suzuki K, Murtuza B, Beauchamp JR, Brand NJ, Barton PJ, Varela-Carver A, et al. Role of interleukin-1beta in acute inflammation and graft death after cell transplantation to the heart. Circulation. 2004;110:II219-24. (Pubitemid 39263726)
48. Li SH, Lai TY, Sun Z, Han M, Moriyama E, Wilson B, et al. Tracking cardiac engraftment and distribution of implanted bone marrow cells: comparing intra-aortic, intravenous, and intramyocardial delivery. J Thorac Cardiovasc Surg. 2009;137:1225-33.
49. Teng CJ, Luo J, Chiu RC, Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. J Thorac Cardiovasc Surg. 2006;132:628-32. (Pubitemid 44278933)
50. Ingber DE. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res. 2002;91:877-87. (Pubitemid 35373587)
51. Ciulla MM, Montelatici E, Ferrero S, Braidotti P, Paliotti R, Annoni G, et al. Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction. J Transl Med. 2008;6:30.
52. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol. 2001;33:907-21. (Pubitemid 32545326)
53. Gyongyosi M, Posa A, Pavo N, Hemetsberger R, Kvakan H, Steiner-Boker S, et al. Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thromb Haemost. 2010;104:376-84.
54. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25:1015-24. (Pubitemid 47517637)
55. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock. 2010;33:24-30.
56. Ren H, Cao Y, Zhao Q, Li J, Zhou C, Liao L, et al. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun. 2006; 347:12-21. (Pubitemid 44040907)
57. + stem cell survival and engraftment in the infarcted heart: dual role for precondi-tioning-induced connexin-43. Circulation. 2009;119:2587-96.
58. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem. 2009;284:33161-8.
59. Ye L, Haider H, Jiang S, Tan RS, Ge R, Law PK, et al. Improved angiogenic response in pig heart following ischae-mic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1. Eur J Heart Fail. 2007;9:15-22. (Pubitemid 46074475)
60. Huang J, Zhang Z, Guo J, Ni A, Deb A, Zhang L, et al. Genetic modification of mesenchymal stem cells overexpress-ing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res. 2010;106:1753-62.
61. Retuerto MA, Schalch P, Patejunas G, Carbray J, Liu N, Esser K, et al. Angiogenic pretreatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardio-myocyte implantation. J Thorac Cardiovasc Surg. 2004;127: 1041-51.
62. Retuerto MA, Beckmann JT, Carbray J, Patejunas G, Sarateanu S, Kane BJ, et al. Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts. J Thorac Cardiovasc Surg. 2007; 133:478-84.
63. Zhu Q, Yu W, Yang X, Hicks GL, Lanzafame RJ, Wang T. Photo-irradiation improved functional preservation of the isolated rat heart. Lasers Surg Med. 1997;20:332-9. (Pubitemid 27200211)
64. Zhang H, Hou JF, Shen Y, Wang W, Wei YJ, Hu S. Low level laser irradiation precondition to create friendly milieu of inf-arcted myocardium and enhance early survival of transplanted bone marrow cells. J Cell Mol Med. 2010;14:1975-87.